Adcock Ingram is a leading South African pharmaceutical manufacturer, listed on the Johannesburg Stock Exchange.
The Company manufactures, markets and distributes a wide range of healthcare products. The company is a leading supplier to both the private and public sectors of the market.
Adcock Ingram is a level 3 B-BBEE contributor.
Adcock Ingram Specialized Therapies is a specialized division that focuses on inspired therapeutic solutions, delivered through innovation that adds value to life, for life.
We provide leadership through solutions that support healthcare professionals to provide best-in-class specialist solutions for comprehensive patient care and the world’s leading and most trusted therapeutic brands.
The Prescription product range comprises medicines and technologies promoted to the healthcare professionals only. This portfolio includes a comprehensive range of generic medicines including antiretroviral medicines (ARVs). Partnerships with multinational pharmaceutical companies continue to augment the comprehensive portfolio of originator medicines.
Contact Details
Telephone: +27 11 635 0000
Physical address:
1 New Road,
Midrand 1685
South Africa
Postal address:
Private Bag X69,
Bryanston 2021
Medicines for Africa’s Lenias Hwenda reflects on Moderna’s recent decision not to go ahead with plans for a vaccine manufacturing facility in Kenya, and why local production remains crucial to…
Medicines for Africa’s Lenias Hwenda argues that the success of the much-talked-about African Medicines Agency hinges on a critical mass of African national regulators achieving WHO Level 3 maturity status.…
Writing in the February 2024 edition of the DIA Global Forum magazine, Verena Pfaffinger and Ilona Baraniak-Lang of PharmaLex examine how the drug shortages seen in the global south during…
Tremendous strides have been made in both treatment and prevention of AIDS and it is no longer among the 10 leading causes of death globally, however an estimated 39 million…
Dr Benji Pretorius, the founder of Erada Technology Alliance and a malaria survivor himself, shares his insights into why the development of a truly effective malaria vaccine will only succeed…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Nevena Miletic of Roche and the IFPMA’s Africa Regulatory Network and Ian Hudson from the Bill and Melinda Gates…
The third and final piece in Lenias Hwenda of Medicines for Africa’s series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential…
The second in a three-part series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come (read part one…
In the first of a series looking back at the challenges and successes of HIV/AIDS treatments over the past 40 years and potential medical breakthroughs to come, Lenias Hwenda of…
During the COVID-19 pandemic discussions around increasing access to medicines for low and middle-income countries (LMICs) were often centred on compulsory licensing. As a result, pharma companies were up in…
As part of a special focus on drug development and clinical research in Africa in February 2023’s DIA Global Forum magazine, Lisa Ursella Collins of Innomas Clinical Research, Leslie Sam…
Roughly half of Africa’s 1.1 billion people lack regular access to even the most essential medicines and most of Sub-Saharan Africa depends on imports which make up as much as…
See our Cookie Privacy Policy Here
